<DOC>
	<DOCNO>NCT01261403</DOCNO>
	<brief_summary>The primary objective study assess safety efficacy 2 dose group ( PDA001 versus vehicle control ) subject active rheumatoid Arthritis . The secondary objective study determine clinical response define visit interval , determine time flare RA symptom quantify change inflammatory marker include C-reactive protein ( CRP ) , erythrocyte sedimentation rate ( ESR ) , serum amyloid A ( SAA ) , IL-6 .</brief_summary>
	<brief_title>Study Human Placenta-derived Cells ( PDA001 ) Evaluate Safety Effectiveness Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Diagnosis RA define 1987revised ACR criterion . 2 . RA , characterize least 6 66 swollen joint 6 68 tender joint Screening Baseline , least 2 follow : C reactive protein level ( CRP ) , great upper limit normal ( ULN ) ³ 1 mg/dl , erythrocyte sedimentation rate ( ESR ) least 28 mm per hour , morning stiffness lasting longer 45 minute . 3 . Non responsive intolerant minimum 2 RA therapy classify DMARDs , biologics , corticosteroid . 4 . Biological medication must discontinue 30 day prior first dose study drug , except golimumab actemra 60 day , infliximab , alefacept efalizumab , must discontinue 90 day prior first dose IP . 5 . Cytotoxic agent , include limited chlorambucil , cyclophosphamide , nitrogen mustard , alkylating agent must discontinue 90 day prior first dose IP . 6 . Subjects must able tolerate intravenous infusion arm . 7 . There change RA medication dose anticipated initial treatment treatment period respective 12 week followup period dose treatment period . The following rule apply antirheumatic medication take study : 8 . DMARDs must must stable least 90 day prior dose IP . 9 . Low dose corticosteroid permit ( prednisolone ≤ 10 mg per day equivalent ) . Corticosteroids must stable least 30 day prior dose IP . 10 . DMARDs corticosteroid must remain stable throughout initial 3 month study throughout subsequent treatment period The presence follow exclude subject enrollment : 1 . Prior use rituximab Bcell deplete therapy , abatacept , prior use 2 biologic therapy . 2 . Subject receive investigational agent indicationwithin 60 day ( 5 halflives , whichever long ) prior treatment IP . 3 . Subject receive previous cell therapy . 4 . Serum creatinine concentration &gt; 2.0 mg/dl screening . 5 . Alkaline phosphatase &gt; 2.5x upper limit normal screening . 6 . Bilirubin level &gt; 1.5 mg/dL ( unless subject know Gilbert 's disease ) . 7 . Untreated chronic infection treatment infection antibiotic within 4 week prior dose IP . 8 . Positive HIV test Screening . Positive Hepatitis B surface antigen Screening . Positive Hepatitis C antibody Screening . 9 . Organic heart disease ( e.g. , congestive heart failure ) , myocardial infarction within six ( 6 ) month prior screen clinically significant finding ECG screening . Clinically significant arrhythmia . 10 . Primary secondary immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Human Placenta-Derived Cells</keyword>
</DOC>